Disease Information
      General Information of the Disease (ID: DIS00100)
  
  | Name | 
               Retina cancer 
             | 
          
|---|---|
| ICD | 
             ICD-11: 2D02 
           | 
        
      Type(s) of Resistant Mechanism of This Disease
  
  
      Drug Resistance Data Categorized by Drug
  
      Approved Drug(s)
      5 drug(s) in total
      
    | Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
| 
                
             | 
          
        ||||
| Key Molecule: hsa-mir-34 | [1] | |||
| Sensitive Disease | Retinoblastoma [ICD-11: 2D02.2] | |||
| Molecule Alteration | Expression | Up-regulation  | 
            ||
| Sensitive Drug | Carboplatin | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
| MAGE-A/p53 signaling pathway | Regulation | hsa04115 | ||
| In Vitro Model | HXO-Rb44 cells | Retina | Homo sapiens (Human) | CVCL_D542 | 
| SO-Rb50 cells | Retina | Homo sapiens (Human) | CVCL_D543 | |
| WERI-Rb-1 cells | Retina | Homo sapiens (Human) | CVCL_1792 | |
| Y79 cells | Retina | Homo sapiens (Human) | CVCL_1893 | |
| Experiment for Molecule Alteration  | 
            RT-qPCR | |||
| Experiment for Drug Resistance  | 
            Freedom Evolyzer-2200 Enzyme-Linked Immunometric meter; Flow cytometry assay | |||
| Mechanism Description | miR-34a may function as a tumor suppressor for RB by targeting MAGE-A and upregulating p53 expression to enhance cell apoptosis and chemosensitivity (Carboplatin; Etoposide; Adriamycin; vincristine). | |||
| Key Molecule: hsa-miR-3163 | [2] | |||
| Sensitive Disease | Retinoblastoma [ICD-11: 2D02.2] | |||
| Molecule Alteration | Expression | Up-regulation  | 
            ||
| Sensitive Drug | Carboplatin | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
| Cell proliferation | Inhibition | hsa05200 | ||
| In Vitro Model | WERI-Rb-1 cells | Retina | Homo sapiens (Human) | CVCL_1792 | 
| Experiment for Molecule Alteration  | 
            RT-PCR | |||
| Experiment for Drug Resistance  | 
            CCK8 assay | |||
| Mechanism Description | Silencing of ABCG2 by MicroRNA-3163 inhibits multidrug resistance in retinoblastoma cancer stem cells. | |||
| 
                
             | 
          
        ||||
| Key Molecule: ATP-binding cassette sub-family G2 (ABCG2) | [2] | |||
| Sensitive Disease | Retinoblastoma [ICD-11: 2D02.2] | |||
| Molecule Alteration | Expression | Down-regulation  | 
            ||
| Sensitive Drug | Carboplatin | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
| Cell proliferation | Inhibition | hsa05200 | ||
| In Vitro Model | WERI-Rb-1 cells | Retina | Homo sapiens (Human) | CVCL_1792 | 
| In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
| Experiment for Molecule Alteration  | 
            Western blot analysis | |||
| Experiment for Drug Resistance  | 
            CCK8 assay | |||
| Mechanism Description | Silencing of ABCG2 by MicroRNA-3163 inhibits multidrug resistance in retinoblastoma cancer stem cells. | |||
| 
                
             | 
          
        ||||
| Key Molecule: Melanoma antigen A 4 (MAGE4) | [1] | |||
| Sensitive Disease | Retinoblastoma [ICD-11: 2D02.2] | |||
| Molecule Alteration | Expression | Up-regulation  | 
            ||
| Sensitive Drug | Carboplatin | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
| MAGE-A/p53 signaling pathway | Regulation | hsa04115 | ||
| In Vitro Model | HXO-Rb44 cells | Retina | Homo sapiens (Human) | CVCL_D542 | 
| SO-Rb50 cells | Retina | Homo sapiens (Human) | CVCL_D543 | |
| WERI-Rb-1 cells | Retina | Homo sapiens (Human) | CVCL_1792 | |
| Y79 cells | Retina | Homo sapiens (Human) | CVCL_1893 | |
| Experiment for Molecule Alteration  | 
            Western blot analysis; RT-qPCR | |||
| Experiment for Drug Resistance  | 
            Freedom Evolyzer-2200 Enzyme-Linked Immunometric meter; Flow cytometry assay | |||
| Mechanism Description | miR-34a may function as a tumor suppressor for RB by targeting MAGE-A and upregulating p53 expression to enhance cell apoptosis and chemosensitivity (Carboplatin; Etoposide; Adriamycin; vincristine). | |||
| Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
| 
                
             | 
          
        ||||
| Key Molecule: hsa-miR-3163 | [2] | |||
| Sensitive Disease | Retinoblastoma [ICD-11: 2D02.2] | |||
| Molecule Alteration | Expression | Up-regulation  | 
            ||
| Sensitive Drug | Cisplatin | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
| Cell proliferation | Inhibition | hsa05200 | ||
| In Vitro Model | WERI-Rb-1 cells | Retina | Homo sapiens (Human) | CVCL_1792 | 
| Experiment for Molecule Alteration  | 
            RT-PCR | |||
| Experiment for Drug Resistance  | 
            CCK8 assay | |||
| Mechanism Description | Silencing of ABCG2 by MicroRNA-3163 inhibits multidrug resistance in retinoblastoma cancer stem cells. | |||
| 
                
             | 
          
        ||||
| Key Molecule: ATP-binding cassette sub-family G2 (ABCG2) | [2] | |||
| Sensitive Disease | Retinoblastoma [ICD-11: 2D02.2] | |||
| Molecule Alteration | Expression | Down-regulation  | 
            ||
| Sensitive Drug | Cisplatin | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
| Cell proliferation | Inhibition | hsa05200 | ||
| In Vitro Model | WERI-Rb-1 cells | Retina | Homo sapiens (Human) | CVCL_1792 | 
| In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
| Experiment for Molecule Alteration  | 
            Western blot analysis | |||
| Experiment for Drug Resistance  | 
            CCK8 assay | |||
| Mechanism Description | Silencing of ABCG2 by MicroRNA-3163 inhibits multidrug resistance in retinoblastoma cancer stem cells. | |||
| Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
| 
                
             | 
          
        ||||
| Key Molecule: hsa-mir-34 | [1] | |||
| Sensitive Disease | Retinoblastoma [ICD-11: 2D02.2] | |||
| Molecule Alteration | Expression | Up-regulation  | 
            ||
| Sensitive Drug | Doxorubicin | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
| MAGE-A/p53 signaling pathway | Regulation | hsa04115 | ||
| In Vitro Model | HXO-Rb44 cells | Retina | Homo sapiens (Human) | CVCL_D542 | 
| SO-Rb50 cells | Retina | Homo sapiens (Human) | CVCL_D543 | |
| WERI-Rb-1 cells | Retina | Homo sapiens (Human) | CVCL_1792 | |
| Y79 cells | Retina | Homo sapiens (Human) | CVCL_1893 | |
| Experiment for Molecule Alteration  | 
            RT-qPCR | |||
| Experiment for Drug Resistance  | 
            Freedom Evolyzer-2200 Enzyme-Linked Immunometric meter; Flow cytometry assay | |||
| Mechanism Description | miR-34a may function as a tumor suppressor for RB by targeting MAGE-A and upregulating p53 expression to enhance cell apoptosis and chemosensitivity (Carboplatin; Etoposide; Adriamycin; vincristine). | |||
| Key Molecule: hsa-miR-3163 | [2] | |||
| Sensitive Disease | Retinoblastoma [ICD-11: 2D02.2] | |||
| Molecule Alteration | Expression | Up-regulation  | 
            ||
| Sensitive Drug | Doxorubicin | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
| Cell proliferation | Inhibition | hsa05200 | ||
| In Vitro Model | WERI-Rb-1 cells | Retina | Homo sapiens (Human) | CVCL_1792 | 
| Experiment for Molecule Alteration  | 
            RT-PCR | |||
| Experiment for Drug Resistance  | 
            CCK8 assay | |||
| Mechanism Description | Silencing of ABCG2 by MicroRNA-3163 inhibits multidrug resistance in retinoblastoma cancer stem cells. | |||
| 
                
             | 
          
        ||||
| Key Molecule: ATP-binding cassette sub-family G2 (ABCG2) | [2] | |||
| Sensitive Disease | Retinoblastoma [ICD-11: 2D02.2] | |||
| Molecule Alteration | Expression | Down-regulation  | 
            ||
| Sensitive Drug | Doxorubicin | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
| Cell proliferation | Inhibition | hsa05200 | ||
| In Vitro Model | WERI-Rb-1 cells | Retina | Homo sapiens (Human) | CVCL_1792 | 
| In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
| Experiment for Molecule Alteration  | 
            Western blot analysis | |||
| Experiment for Drug Resistance  | 
            CCK8 assay | |||
| Mechanism Description | Silencing of ABCG2 by MicroRNA-3163 inhibits multidrug resistance in retinoblastoma cancer stem cells. | |||
| 
                
             | 
          
        ||||
| Key Molecule: Melanoma antigen A 4 (MAGE4) | [1] | |||
| Sensitive Disease | Retinoblastoma [ICD-11: 2D02.2] | |||
| Molecule Alteration | Expression | Up-regulation  | 
            ||
| Sensitive Drug | Doxorubicin | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
| MAGE-A/p53 signaling pathway | Regulation | hsa04115 | ||
| In Vitro Model | HXO-Rb44 cells | Retina | Homo sapiens (Human) | CVCL_D542 | 
| SO-Rb50 cells | Retina | Homo sapiens (Human) | CVCL_D543 | |
| WERI-Rb-1 cells | Retina | Homo sapiens (Human) | CVCL_1792 | |
| Y79 cells | Retina | Homo sapiens (Human) | CVCL_1893 | |
| Experiment for Molecule Alteration  | 
            Western blot analysis; RT-qPCR | |||
| Experiment for Drug Resistance  | 
            Freedom Evolyzer-2200 Enzyme-Linked Immunometric meter; Flow cytometry assay | |||
| Mechanism Description | miR-34a may function as a tumor suppressor for RB by targeting MAGE-A and upregulating p53 expression to enhance cell apoptosis and chemosensitivity (Carboplatin; Etoposide; Adriamycin; vincristine). | |||
| Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
| 
                
             | 
          
        ||||
| Key Molecule: hsa-mir-34 | [1] | |||
| Sensitive Disease | Retinoblastoma [ICD-11: 2D02.2] | |||
| Molecule Alteration | Expression | Up-regulation  | 
            ||
| Sensitive Drug | Etoposide | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
| MAGE-A/p53 signaling pathway | Regulation | hsa04115 | ||
| In Vitro Model | HXO-Rb44 cells | Retina | Homo sapiens (Human) | CVCL_D542 | 
| SO-Rb50 cells | Retina | Homo sapiens (Human) | CVCL_D543 | |
| WERI-Rb-1 cells | Retina | Homo sapiens (Human) | CVCL_1792 | |
| Y79 cells | Retina | Homo sapiens (Human) | CVCL_1893 | |
| Experiment for Molecule Alteration  | 
            RT-qPCR | |||
| Experiment for Drug Resistance  | 
            Freedom Evolyzer-2200 Enzyme-Linked Immunometric meter; Flow cytometry assay | |||
| Mechanism Description | miR-34a may function as a tumor suppressor for RB by targeting MAGE-A and upregulating p53 expression to enhance cell apoptosis and chemosensitivity (Carboplatin; Etoposide; Adriamycin; vincristine). | |||
| Key Molecule: hsa-miR-3163 | [2] | |||
| Sensitive Disease | Retinoblastoma [ICD-11: 2D02.2] | |||
| Molecule Alteration | Expression | Up-regulation  | 
            ||
| Sensitive Drug | Etoposide | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
| Cell proliferation | Inhibition | hsa05200 | ||
| In Vitro Model | WERI-Rb-1 cells | Retina | Homo sapiens (Human) | CVCL_1792 | 
| Experiment for Molecule Alteration  | 
            RT-PCR | |||
| Experiment for Drug Resistance  | 
            CCK8 assay | |||
| Mechanism Description | Silencing of ABCG2 by MicroRNA-3163 inhibits multidrug resistance in retinoblastoma cancer stem cells. | |||
| 
                
             | 
          
        ||||
| Key Molecule: ATP-binding cassette sub-family G2 (ABCG2) | [2] | |||
| Sensitive Disease | Retinoblastoma [ICD-11: 2D02.2] | |||
| Molecule Alteration | Expression | Down-regulation  | 
            ||
| Sensitive Drug | Etoposide | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
| Cell proliferation | Inhibition | hsa05200 | ||
| In Vitro Model | WERI-Rb-1 cells | Retina | Homo sapiens (Human) | CVCL_1792 | 
| In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
| Experiment for Molecule Alteration  | 
            Western blot analysis | |||
| Experiment for Drug Resistance  | 
            CCK8 assay | |||
| Mechanism Description | Silencing of ABCG2 by MicroRNA-3163 inhibits multidrug resistance in retinoblastoma cancer stem cells. | |||
| 
                
             | 
          
        ||||
| Key Molecule: Melanoma antigen A 4 (MAGE4) | [1] | |||
| Sensitive Disease | Retinoblastoma [ICD-11: 2D02.2] | |||
| Molecule Alteration | Expression | Up-regulation  | 
            ||
| Sensitive Drug | Etoposide | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
| MAGE-A/p53 signaling pathway | Regulation | hsa04115 | ||
| In Vitro Model | HXO-Rb44 cells | Retina | Homo sapiens (Human) | CVCL_D542 | 
| SO-Rb50 cells | Retina | Homo sapiens (Human) | CVCL_D543 | |
| WERI-Rb-1 cells | Retina | Homo sapiens (Human) | CVCL_1792 | |
| Y79 cells | Retina | Homo sapiens (Human) | CVCL_1893 | |
| Experiment for Molecule Alteration  | 
            Western blot analysis; RT-qPCR | |||
| Experiment for Drug Resistance  | 
            Freedom Evolyzer-2200 Enzyme-Linked Immunometric meter; Flow cytometry assay | |||
| Mechanism Description | miR-34a may function as a tumor suppressor for RB by targeting MAGE-A and upregulating p53 expression to enhance cell apoptosis and chemosensitivity (Carboplatin; Etoposide; Adriamycin; vincristine). | |||
| Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
| 
                
             | 
          
        ||||
| Key Molecule: hsa-mir-34 | [1] | |||
| Sensitive Disease | Retinoblastoma [ICD-11: 2D02.2] | |||
| Molecule Alteration | Expression | Up-regulation  | 
            ||
| Sensitive Drug | Vincristine | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
| MAGE-A/p53 signaling pathway | Regulation | hsa04115 | ||
| In Vitro Model | HXO-Rb44 cells | Retina | Homo sapiens (Human) | CVCL_D542 | 
| SO-Rb50 cells | Retina | Homo sapiens (Human) | CVCL_D543 | |
| WERI-Rb-1 cells | Retina | Homo sapiens (Human) | CVCL_1792 | |
| Y79 cells | Retina | Homo sapiens (Human) | CVCL_1893 | |
| Experiment for Molecule Alteration  | 
            RT-qPCR | |||
| Experiment for Drug Resistance  | 
            Freedom Evolyzer-2200 Enzyme-Linked Immunometric meter; Flow cytometry assay | |||
| Mechanism Description | miR-34a may function as a tumor suppressor for RB by targeting MAGE-A and upregulating p53 expression to enhance cell apoptosis and chemosensitivity (Carboplatin; Etoposide; Adriamycin; vincristine). | |||
| Key Molecule: hsa-miR-3163 | [2] | |||
| Sensitive Disease | Retinoblastoma [ICD-11: 2D02.2] | |||
| Molecule Alteration | Expression | Up-regulation  | 
            ||
| Sensitive Drug | Vincristine | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
| Cell proliferation | Inhibition | hsa05200 | ||
| In Vitro Model | WERI-Rb-1 cells | Retina | Homo sapiens (Human) | CVCL_1792 | 
| Experiment for Molecule Alteration  | 
            RT-PCR | |||
| Experiment for Drug Resistance  | 
            CCK8 assay | |||
| Mechanism Description | Silencing of ABCG2 by MicroRNA-3163 inhibits multidrug resistance in retinoblastoma cancer stem cells. | |||
| 
                
             | 
          
        ||||
| Key Molecule: ATP-binding cassette sub-family G2 (ABCG2) | [2] | |||
| Sensitive Disease | Retinoblastoma [ICD-11: 2D02.2] | |||
| Molecule Alteration | Expression | Down-regulation  | 
            ||
| Sensitive Drug | Vincristine | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
| Cell proliferation | Inhibition | hsa05200 | ||
| In Vitro Model | WERI-Rb-1 cells | Retina | Homo sapiens (Human) | CVCL_1792 | 
| In Vivo Model | Nude mouse xenograft model | Mus musculus | ||
| Experiment for Molecule Alteration  | 
            Western blot analysis | |||
| Experiment for Drug Resistance  | 
            CCK8 assay | |||
| Mechanism Description | Silencing of ABCG2 by MicroRNA-3163 inhibits multidrug resistance in retinoblastoma cancer stem cells. | |||
| 
                
             | 
          
        ||||
| Key Molecule: Melanoma antigen A 4 (MAGE4) | [1] | |||
| Sensitive Disease | Retinoblastoma [ICD-11: 2D02.2] | |||
| Molecule Alteration | Expression | Up-regulation  | 
            ||
| Sensitive Drug | Vincristine | |||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| Cell Pathway Regulation | Cell apoptosis | Activation | hsa04210 | |
| MAGE-A/p53 signaling pathway | Regulation | hsa04115 | ||
| In Vitro Model | HXO-Rb44 cells | Retina | Homo sapiens (Human) | CVCL_D542 | 
| SO-Rb50 cells | Retina | Homo sapiens (Human) | CVCL_D543 | |
| WERI-Rb-1 cells | Retina | Homo sapiens (Human) | CVCL_1792 | |
| Y79 cells | Retina | Homo sapiens (Human) | CVCL_1893 | |
| Experiment for Molecule Alteration  | 
            Western blot analysis; RT-qPCR | |||
| Experiment for Drug Resistance  | 
            Freedom Evolyzer-2200 Enzyme-Linked Immunometric meter; Flow cytometry assay | |||
| Mechanism Description | miR-34a may function as a tumor suppressor for RB by targeting MAGE-A and upregulating p53 expression to enhance cell apoptosis and chemosensitivity (Carboplatin; Etoposide; Adriamycin; vincristine). | |||
      References
  
  visits since 2022
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.
